Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
McKesson
Harvard Business School
Merck
Deloitte
Cipla
McKinsey
Baxter
Queensland Health
Fish and Richardson

Generated: August 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Tamper resistant dosage forms
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Inventor(s): McKenna; William H. (Yonkers, NY), Mannion; Richard O. (Furlong, PA), O'Donnell; Edward P. (Basking Ridge, NJ), Huang; Haiyong H. (Princeton, NJ)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Filing Date:May 23, 2013
Application Number:13/901,078
Claims:1. A convection cured shaped tablet comprising an extended release matrix comprising a composition, wherein said tablet comprises: (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000, and (2) hydrocodone or a pharmaceutically acceptable salt, and wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend to form a shaped tablet; and (c) convection curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 8 hours, wherein said convection cured shaped tablet comprises at least 80% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000.

2. A convection cured shaped tablet as defined in claim 1, wherein said hydrocodone or pharmaceutically acceptable salt is hydrocodone bitartrate.

3. A convection cured shaped tablet as defined in claim 1, wherein said time in said curing step is 30 minutes to 90 minutes.

4. A convection cured shaped tablet as defined in claim 1, wherein said temperature in said curing step is from 62 to 90.degree. C.

5. A convection cured shaped tablet as defined in claim 1, wherein said shaped tablet is coated before or after said curing step.

6. A convection cured shaped tablet as defined in claim 1, wherein said convection cured shaped tablet comprises a once-a-day dosage form.

7. A convection cured shaped tablet as defined in claim 1, wherein said convection cured shaped tablet comprises a twice-a-day dosage form.

8. A convection cured shaped tablet as defined in claim 1, wherein said tablet is shaped by compression.

9. A convection cured shaped tablet as defined in claim 1, wherein the density of the extended release matrix of said convection cured shaped tablet is lower than the density of the extended release matrix of said shaped tablet prior to curing.

10. A convection cured shaped tablet comprising an extended release matrix comprising a composition, wherein said tablet comprises: (1) at least 80% by weight, based upon the total weight of said composition, of at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000, and (2) hydrocodone bitartrate; wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend to form a shaped tablet; and (c) convection curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 8 hours.

11. A convection cured shaped tablet as defined in claim 10, wherein, said temperature in said curing step is from 62 to 90.degree. C.

12. A convection cured shaped tablet as defined in claim 10, wherein said shaped tablet is coated before or after said curing step.

13. A cured shaped tablet as defined in claim 10, wherein said tablet is shaped by compression.

14. A convection cured shaped tablet as defined in claim 10, wherein the density of the extended release matrix of said convection cured shaped tablet is lower, by at least 0.5%, than the density of the extended release matrix of said shaped tablet prior to curing.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Cantor Fitzgerald
Healthtrust
Cipla
McKesson
Moodys
Deloitte
Mallinckrodt
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot